4BASEBIO PLC (88Q.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:88Q • GB00BMCLYF79
6.3 EUR
-0.25 (-3.82%)
Last: Jan 26, 2026, 07:00 PM
Taking everything into account, 88Q scores 3 out of 10 in our fundamental rating. 88Q was compared to 85 industry peers in the Biotechnology industry. The financial health of 88Q is average, but there are quite some concerns on its profitability. 88Q is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
- 88Q had negative earnings in the past year.
- 88Q had a negative operating cash flow in the past year.
- 88Q had negative earnings in each of the past 5 years.
- 88Q had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -39.08%, 88Q perfoms like the industry average, outperforming 41.18% of the companies in the same industry.
- 88Q has a Return On Equity of -75.90%. This is comparable to the rest of the industry: 88Q outperforms 54.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.08% | ||
| ROE | -75.9% | ||
| ROIC | N/A |
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- 88Q has a Gross Margin of 61.55%. This is comparable to the rest of the industry: 88Q outperforms 51.76% of its industry peers.
- In the last couple of years the Gross Margin of 88Q has declined.
- The Profit Margin and Operating Margin are not available for 88Q so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- 88Q does not have a ROIC to compare to the WACC, probably because it is not profitable.
- 88Q has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, 88Q has more shares outstanding
- 88Q has a better debt/assets ratio than last year.
2.2 Solvency
- 88Q has an Altman-Z score of 1.23. This is a bad value and indicates that 88Q is not financially healthy and even has some risk of bankruptcy.
- 88Q has a Altman-Z score of 1.23. This is in the better half of the industry: 88Q outperforms 63.53% of its industry peers.
- A Debt/Equity ratio of 0.81 indicates that 88Q is somewhat dependend on debt financing.
- The Debt to Equity ratio of 88Q (0.81) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.23 |
ROIC/WACCN/A
WACC8.3%
2.3 Liquidity
- 88Q has a Current Ratio of 11.36. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.
- 88Q has a better Current ratio (11.36) than 95.29% of its industry peers.
- A Quick Ratio of 11.15 indicates that 88Q has no problem at all paying its short term obligations.
- 88Q has a better Quick ratio (11.15) than 95.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.36 | ||
| Quick Ratio | 11.15 |
3. Growth
3.1 Past
- The earnings per share for 88Q have decreased strongly by -26.52% in the last year.
- 88Q shows a strong growth in Revenue. In the last year, the Revenue has grown by 198.49%.
- Measured over the past years, 88Q shows a very strong growth in Revenue. The Revenue has been growing by 35.80% on average per year.
EPS 1Y (TTM)-26.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.8%
Revenue 1Y (TTM)198.49%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%257.93%
3.2 Future
- 88Q is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.46% yearly.
- 88Q is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 96.38% yearly.
EPS Next Y-34.32%
EPS Next 2Y-7.14%
EPS Next 3Y2.5%
EPS Next 5Y10.46%
Revenue Next Year50%
Revenue Next 2Y141.52%
Revenue Next 3Y132.08%
Revenue Next 5Y96.38%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- 88Q reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year 88Q is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.14%
EPS Next 3Y2.5%
5. Dividend
5.1 Amount
- 88Q does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
4BASEBIO PLC / 88Q.DE FAQ
Can you provide the ChartMill fundamental rating for 4BASEBIO PLC?
ChartMill assigns a fundamental rating of 3 / 10 to 88Q.DE.
Can you provide the valuation status for 4BASEBIO PLC?
ChartMill assigns a valuation rating of 0 / 10 to 4BASEBIO PLC (88Q.DE). This can be considered as Overvalued.
How profitable is 4BASEBIO PLC (88Q.DE) stock?
4BASEBIO PLC (88Q.DE) has a profitability rating of 1 / 10.
What is the earnings growth outlook for 4BASEBIO PLC?
The Earnings per Share (EPS) of 4BASEBIO PLC (88Q.DE) is expected to decline by -34.32% in the next year.